Table 5

Summary of clinical trials where imatinib mesylate (Gleevec, Novartis) was tested in patients with adenoid cystic carcinoma of salivary glands

Type of trialEnrolled patientsc-KIT expression by IHCKIT or PDFRA mutationsImatinib doseResultsReference
Multicentre single arm, two stage phase II clinical trialPatients (N=16) with unresectable or metastatic AdCCPresentNP400 mg×2 dailyNo evidence of objective response in 15 assessable patients. Early termination after completion of the first stageHotte et al, 2005107
Phase II study with combination of imatinib mesylate and cisplatinN=14PresentNP800 mg as single agent; 400 mg in combination with cisplatin 80 mg/m2Of the 12 assessable patients, 2 developed DP with imatinib as single agent and left the study; 1 had a documented PR; 4 had reduction in tumour size; the others showed SD (but short follow-up)Slevin et al, 2004108
Pilot studyPatients (N=5) with metastatic AdCCPresentNo400 mg×2 dailyDP in 2/5; DOD in 3/5.Lin et al, 2005105
Phase II study for advanced AdCC of head and neck salivary glandsPatients (N= 10) with locally advanced or metastatic AdCCPresentNP400 mg (increased to 600 mg in 3 patients and to 800 mg in 1 patient)2/10 patients with SD; 8/10 patients stopped the treatment after 2–14 months due to DPPfeffer et al, 2007106
Multicentre phase II trialPatients (N=8) with recurrent or metastatic AdCCPresentNP400 mg×2 dailyAmong the 6 assessable patients, 3 showed SD after 3 months of follow-up, one had a PRFaivre et al, 2005104
  • DOD, death of disease; DP, disease progression; IHC, immunohistochemistry; NP, not performed; PR, partial response; SD, stable disease.